Interleukin-6: a critical cytokine in cancer multidrug resistance

M Ghandadi, A Sahebkar - Current pharmaceutical design, 2016 - ingentaconnect.com
Multidrug resistance (MDR) is a phenomenon through which tumor cells develop resistance
against the cytotoxic effects of various structurally and mechanistically unrelated …
被引用次数：83 相关文章

[引用][C] Interleukin-6: A Critical Cytokine in Cancer Multidrug Resistance

M Ghandadi, A Sahebkar - Current Pharmaceutical Design, 2016 - cir.nii.ac.jp
Interleukin-6: A Critical Cytokine in Cancer Multidrug Resistance | CiNii Research CiNii 国立
情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす …

Interleukin-6: A critical cytokine in cancer multidrug resistance

M Ghandadi, A Sahebkar - Current …, 2016 - research-repository.uwa.edu.au
Abstract© 2016 Bentham Science Publishers. Multidrug resistance (MDR) is a phenomenon
through which tumor cells develop resistance against the cytotoxic effects of various …

Interleukin-6: A Critical Cytokine in Cancer Multidrug Resistance.

M Ghandadi, A Sahebkar - Current Pharmaceutical Design, 2016 - europepmc.org
Multidrug resistance (MDR) is a phenomenon through which tumor cells develop resistance
against the cytotoxic effects of various structurally and mechanistically unrelated …

Interleukin-6: A Critical Cytokine in Cancer Multidrug Resistance

M Ghandadi, A Sahebkar - Current pharmaceutical …, 2016 - pubmed.ncbi.nlm.nih.gov
Multidrug resistance (MDR) is a phenomenon through which tumor cells develop resistance
against the cytotoxic effects of various structurally and mechanistically unrelated …